Cytokinetics is a biopharmaceutical company with a focus on the discovery, development, and commercialization of muscle activators and muscle inhibitors as potential treatments for debilitating diseases wherein muscle performance is affected. The company develops small molecule drug candidates designed to affect muscle function and contractility. Cytokinetics is developing aficamten, a next-generation cardiac myosin inhibitor, to treat hypertrophic cardiomyopathy (HCM). It is also developing reldesemtiv, a fast skeletal muscle troponin activator, for the treatment of ALS patients. The company has licensing and collaboration agreements with Amgen, Ji Xing, and Astellas for advancing its drug candidates. Cytokinetics is headquartered in South San Francisco, California, the US.
Headquarters
United States of America
Address
., 280 East Grand Avenue, South San Francisco, California, 94080
Website
cytokinetics.com
Telephone
1 650 6243000
No of Employees
253
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
CYTK (NASD)
Revenue (2021)
$70.4M
26.2%
(2021 vs 2020)
EPS
XXX
Net Income (2021)
XXX
-69.2%
(2021 vs 2020)
Market Cap*
$3.7B
Net Profit Margin (2021)
XXX
-34.1%
(2021 vs 2020)
* As of and is in US$
Explore premium data & analytics
Products and Services
| Products |
|---|
| Pipeline |
| Omecamtiv Mecarbil: Heart Failure |
| Reldesemtiv: Spinal Muscular Atrophy and Chronic Obstructive Pulmonary Disease |
| XXX |
| XXX |
| XXX |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2022 | Contracts/Agreements | In May, the company and The ALS Association announced the continuation of their partnership in the fight against ALS. |
| 2022 | Regulatory Approval | In February, the company secured FDA approval for omecamtiv mecarbil, an investigational, selective, small molecule cardiac myosin activator, for the treatment of heart failure with reduced ejection fraction. |
| 2022 | Contracts/Agreements | In February, the company and the American Heart Association (AHA) Bay Area entered into a collaboration to accelerate education and awareness of heart disease. |
Competitor Comparison
| Key Parameters | Cytokinetics Inc | Regeneron Pharmaceuticals Inc | Alexion Pharmaceuticals Inc | Mitsubishi Tanabe Pharma Corp | PTC Therapeutics Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | Japan | United States of America |
| City | South San Francisco | Tarrytown | Boston | Osaka | South Plainfield |
| State/Province | California | New York | Massachusetts | Osaka | New Jersey |
| No. of Employees | 253 | 10,368 | 3,837 | 6,728 | 1,252 |
| Entity Type | Public | Public | Private | Private | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Operating Margin
EPS (Earnings per Share)
Debt to Equity Ratio
Return on Assets
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| John T. Henderson, M.D. | Chairman | Executive Board | 2022 | 77 |
| Robert I. Blum | President; Director; Chief Executive Officer | Executive Board | 2007 | 58 |
| Ching W. Jaw | Senior Vice President; Chief Financial Officer | Senior Management | 2017 | 59 |
| Robert C. Wong | Vice President; Chief Accounting Officer | Senior Management | 2019 | 55 |
| Kari K. Loeser | Chief Compliance Officer; Vice President | Senior Management | 2021 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer